For the year ending 2025-12-31, GH made $982,021K in revenue. -$416,277K in net income. Net profit margin of -42.39%.
| Income Statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | 982,021 | 739,016 | 563,948 | 449,538 |
| Cost of revenue | 349,007 | - | - | - |
| Research and development expense | 364,191 | 347,753 | 367,194 | 373,807 |
| Sales and marketing expense | 494,661 | 364,935 | 295,227 | 299,828 |
| General and administrative expense | 211,410 | 180,123 | 155,800 | 163,956 |
| Cost of precision oncology testing | - | 260,581 | 205,528 | 148,199 |
| Cost of development services and other | - | 29,218 | 21,524 | 8,126 |
| Other operating expense | 0 | 0 | 83,400 | - |
| Total costs and operating expenses | 1,419,269 | 1,182,610 | 1,128,673 | 993,916 |
| Loss from operations | -437,248 | -443,594 | -564,725 | -544,378 |
| Interest income | 34,095 | 53,691 | 35,365 | 6,069 |
| Interest expense | 3,897 | 2,581 | 2,578 | 2,577 |
| Fair value adjustments of noncontrolling interest liability | - | 0 | 0 | -99,785 |
| Other income (expense), net | -10,490 | -42,605 | 53,174 | -12,778 |
| Loss before (benefit from) provision for income taxes | -417,540 | -435,089 | -478,764 | -653,449 |
| (benefit from) provision for income taxes | -1,263 | 1,284 | 685 | 1,139 |
| Net loss | - | - | -479,449 | -654,588 |
| Adjustment of redeemable noncontrolling interest | - | - | 0 | 0 |
| Net loss attributable to guardant health, inc. common stockholders - basic | - | - | - | -654,588 |
| Net loss attributable to guardant health, inc. common stockholders - diluted | - | - | -479,449 | - |
| Net loss | -416,277 | -436,373 | - | - |
| Basic EPS | -3.32 | -3.56 | -4.28 | -6.41 |
| Diluted EPS | -3.32 | -3.56 | -4.28 | -6.41 |
| Basic Average Shares | 125,374,000 | 122,745,000 | 111,988,000 | 102,178,000 |
| Diluted Average Shares | 125,374,000 | 122,745,000 | 111,988,000 | 102,178,000 |
Guardant Health, Inc. (GH)
Guardant Health, Inc. (GH)